OrbitonOpen research workspace →
Atyr Pharma Inc. logo

Atyr Pharma Inc.

NASDAQ:ATYRLive AI agent

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.

Investor website: https://atyrpharma.com/

About

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains to regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. Their lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), which can cause chronic inflammation and progressive fibrosis of the lungs. Efzofitimod selectively modulates activated myeloid cells to resolve inflammation without immune suppression. aTyr is also investigating efzofitimod in pulmonary sarcoidosis and systemic sclerosis-related ILD, with ongoing clinical studies.

Verified company data

Cash position
$58.9 million
Shares outstanding
88,858,612
Projects
["Pangu BioPharma is a subsidiary of aTyr Pharma in Hong Kong. Pangu supports basic and translational research in tRNA synthetase biology in collaboration with the Hong Kong University of Science and Technology (HKUST). Researchers, including experts in molecular biology, genetics and protein structure, have identified many naturally occurring splice variants of human amino-acyl tRNA synthetases and characterized their extracellular signaling functions. The Hong Kong government, through its Innovation and Technology Commission (ITC), has provided financial support for this collaborative work through a two-year grant.\n\nThe project is intended to develop a high-throughput platform for the development of bispecific antibodies with an initial focus on diseases in which Neuropilin-2 (NRP2) overexpression is strongly implicated, including cancer.\n\nIn May 2021, we announced that Pangu and HKUST achieved the milestones set forth for the first year of the project. This included building out a highly skilled research team to establish an innovative antibody discovery platform at HKUST and the development and implementation of a novel single-cell antibody discovery approach which has so far yielded numerous candidate high-affinity NRP2/co-receptor antibodies that are currently being screened in functional assays.\n\nThe second year of the project aims to identify the most productive pairings, optimize mid-scale production/purification and prioritize lead candidate bispecific antibodies based on activity in therapeutically relevant cell-based assays."]
Leadership
Sanjay S. Shukla, M.D., M.S. (President and CEO, Director), Jill M. Broadfoot (Chief Financial Officer), Nancy E. Denyes (General Counsel), Andrea Cubitt, Ph.D. (VP, External Scientific Alliances & Intellectual Property), Peter Villiger (VP, Corporate Development), Leslie Nangle, Ph.D. (VP, Research), Robert W. Ashworth, Ph.D. (VP, Regulatory Affairs), Danielle Campbell (VP, Human Resources), Lisa Carey (VP, Clinical Operations), Dalia R. Rayes (Head of Commercial, Global Efzofitimod Franchise), Darin Lee, Ph.D. (VP, Technical Operations), Brandon Yaras (Vice President, Finance), Timothy P. Coughlin (Chairman), Jane A. Gross, Ph.D. (Director), Svetlana Lucas, Ph.D. (Director), Sara L. Zaknoen, M.D. (Director), Eric Benevich (Director)

Verified data last updated:

Recent filings